Medytox has begun to step up its efforts to achieve Vision 2022.
Based on integrity and open communication, Medytox is building excellent capacity and system to meet the global standard with commitment and courage.
Furthermore, we are endeavoring to reach $1 billion in sales, $10 billion in market value,
and to become one of the world's top 20 biopharmaceutical companies by 2022.
While meeting global quality standards, Medytox has become one of the leading global companies.
* Single-use System: Using single-use sterile bags
to shorten the process
Starting with a Taiwan joint venture "Medytox Taiwan", Medytox established a China joint venture "Medybloom China", a Hong Kong joint venture "Medytox Hong Kong", a Thailand joint venture "MedyCeles", and a 100% owned local subsidiary "MDT International Inc." in Japan.